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ABSTRACT
Bacteria, Archaea, Eukarya and viruses coexist in the human gut, and this coexistence is functionally
balanced by symbiotic or antagonistic relationships. Antagonism is often characterized by the
production of antimicrobials against other organisms occupying the same environmental niche.
Indeed, close co-evolution in the gut has led to the development of specialized antimicrobials,
which is attracting increased attention as these may serve as novel alternatives to antibiotics and
thereby help to address the global problem of antimicrobial resistance. The gastrointestinal (GI)
tract is especially suitable for finding novel antimicrobials due to the vast array of microbes that
inhabit it, and a considerable number of antimicrobial producers of both wide and narrow spectrum
have been described. In this review, we summarize some of the antimicrobial compounds that are
produced by bacteria isolated from the gut environment, with a special focus on bacteriocins. We
also evaluate the potential therapeutic application of these compounds to maintain homeostasis in








Antimicrobials are compounds that kill or inhibit the
growth of microorganisms. The availability of antimi-
crobials, and antibiotics in particular, has improved
the quality of life and increased life expectancy. How-
ever, antibiotic resistance has become a major threat.
Indeed, since the golden era of antibiotic discovery
(1940-1960), when many compounds were discovered,
especially from soil-derived actinomycetes, few new
classes of antibiotics have been discovered, and the
majority of new compounds have resulted from chem-
ical modifications of existing ones. In an effort to
address this challenge, different approaches have been
proposed, like the use of discovery platforms,1 but
there has been insufficient investment globally in
developing novel procedures/techniques to identify
new antimicrobials, and the characterization of these
compounds thereafter.
Traditionally, the production of antimicrobials has
been considered as an expression of competition and
antagonism in bacteria, both inter- and intra-species,
whose niches overlap.2 However, it should also be noted
that some antimicrobials, and antimicrobial peptides in
particular, might have a social purpose, serving to
facilitate signaling between individual strains, although
not necessarily an indication of cooperation.3 Antimi-
crobial activity has been proposed to promote biodiver-
sity, as reflected by the differences in metabolic input of
antimicrobial producers, sensitive and resistant species
and in the ecological fitness that these bacteria show in
a shared environment.4,5 More specifically, production
of antimicrobials might confer an advantage to the pro-
ducer against sensitive bacteria, but this production is
the result of a metabolic effort, as is the maintenance of
immunity among resistant bacteria, which requires less
metabolic input than antimicrobial production, but
more than that of sensitive bacteria. This has been
referred to as the rock-scissors-paper (RSP) dynamic
game that ultimately leads to a balanced co-existence in
microbial communities.4,5 Different studies, both theo-
retical and experimental, have been carried out to
understand the dynamics of the microbial communities
and the role that antibiotics play in this context. These
considerations further support the premise that natural
sources containing a wide diversity of microorganisms
continue to be an underexploited source of new antimi-
crobials that can be identified and developed at an
enhanced rate with the aid of new ‘omics’ technologies,
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computational advances and development of new ana-
lytical tools.6
The human microbiome represents an excellent
example of such an environmental niche and contains
trillions of microorganisms that have co-evolved with
the human host, leading to the view that humans can
be considered to be super-organisms, constituted by a
vast number of symbiotic relationships. Arguably, the
most important microbial communities in humans
can be found in the GI tract (the colon is estimated to
contain over 70% of all the microbes in the human
body7), in the mouth, skin, and urogenitalia. Microbial
communities can be also found in, for example,
lungs, breast milk and eyes.8 These communities are
dynamic and change over time, due to characteristic
processes of ecological succession, where microbial
communities are substituted by new ones and can be
affected by changes of environmental conditions. In
the GI tract, the first microbial species that are estab-
lished in infants are succeeded by new species to form
a more mature and complex community and the bal-
ance can be altered by the use of antibiotics, dietary
changes or introduction of exogenous pathogens.9,10
As the human microbiome is such a dense and
diverse compilation of different microbial ecosystems
that has not yet been fully explored, it is not difficult
to regard it as a promising source of novel metabolites.
In 2015, Donia and Fischbach reviewed the chemical
spectrum of metabolites produced by the human
microbiota and concluded that its diversity was as
broad as any other microbial ecosystem, but that these
metabolites were highly specific for interacting within
the human host.11 More recently, Mousa et al12 (2017)
extensively reviewed the same topic, highlighting the
variety of specialized metabolic compounds produced
by this human microbiota and the effects within the
human host. These metabolites include lipids and gly-
colipids, oligosaccharides, terpenoids, polyketides,
amino acids, non-ribosomal peptides and ribosomally
synthesized post-translationally modified peptides
(RiPPs). This chemical variety also reflects a variety of
functions: immunomodulatory, cytotoxic, antioxidant
and, of course, antimicrobial, although the function of
many of these compounds is not yet identified. New
compounds and functions continue to be discovered
and characterized. Among the vast number of relevant
papers are two recent examples that have shown that a
human nasal commensal produces a novel peptide
antibiotic that is able to limit Staphylococcus aureus
colonization and maintain homeostasis13 and that an
antimicrobial produced by skin commensal bacteria
has potential for the treatment of atopic dermatitis.14
In the latter case, the observations point to dysbiosis
of the skin microbiome as the origin of the problem
and a rebalancing of the situation as a potential
solution.
Given the aforementioned observations, the variety
of species that are coexisting in the human micro-
biome, most densely in the GI tract, and the number
of antimicrobials with a human microbiome origin
that have already been described, we can assume that
the human gut can continue to be a promising source
of new antimicrobials that can help to address specific
aetiologies and complex systemic conditions such as
metabolic syndrome, inflammatory bowel disease,
colorectal cancer and diabetes, that have been started
to be associated with an imbalance in gut microbiota
communities.15
Here we review the variety of antimicrobials pro-
duced by bacteria present in the human GI tract and,
in the process, highlight the importance of a targeted
approach to discover new effective antimicrobials that
can help to maintain good health in humans and to
address the problem of antimicrobial resistance.
2. Gut microbiota composition and distribution
Gut microbiota composition is heterogeneous across
the GI tract as a result of variations in a broad variety
of parameters including fluctuations in temperature,
pH, water activity and gas composition as well as differ-
ences in physiology throughout the gut. Nutrients are a
very important factor because they are the main source
of energy for gut bacteria. Their chemical and physical
nature determines flow rates in the gut and, therefore,
the process of adhesion and washing out of microor-
ganisms. Surface tension can also be affected, having an
effect on the physiology of bacteria. Further information
on gut conditions and how they influence composition
has been extensively reviewed previously.10,16
It is important to consider that the gut microbiota
composition is also not static. As noted earlier, alter-
ation of the microbiome structure starts from the
moments after birth and varies significantly ini-
tially.17,18 However, it stabilizes after the first7 or
third10 year of life, maintaining a relatively consistent
composition that tends to recover even after acute
changes, such as a single exposure to antibiotics.16,17
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More sustained changes, like dietary alterations over
an extended period can, however, induce longer last-
ing structural changes.7
Observations of variation among individuals,
throughout their intestinal tracts and across their life
span, has made it clear that it is challenging to describe
what constitutes a healthy gut microbiota.8 However, it
has been argued that a functional approach to categorize
the gut microbiota may more accurately reflect its
‘health’. This is based on the fact that the microbiota is
capable of carrying out a variety of metabolic andmolec-
ular functions. This functionality is somewhat redun-
dant and thus remains relatively even in situations
where changes in taxonomy are evident.10
There have been considerable advances in approaches
to determine microbial composition and the identifica-
tion of their functional attributes. High throughput new
generation DNA sequencing platforms in particular
have helped to identify, and partially characterize
microbes, most of which cannot be cultured. Care needs
to be taken however as the vast majority of investigations
relating to the human gut microbiota have been per-
formed using stool samples and, as pointed out by Bajaj
et al19 and others, fecal communities do not reflect the
gut mucosal microbiota or microbial communities at
locations in the upper sections of the GI tract.16
In general, the dominant bacterial phyla in the gut are
Bacteroidetes, Firmicutes, Actinobacteria, Proteobacte-
ria and Verrucomicrobia.16 Differences in physiological
conditions result in a heterogeneous distribution of
bacteria across the GI tract. The presence of bile acids,
lower pH, higher oxygen levels and antimicrobial com-
pounds (of both host and bacterial origin) favors coloni-
zation of the small intestine by groups of facultative
anaerobes, such as Firmicutes (Lactobacillales) and Pro-
teobacteria (Enterobacteriales). In the proximal part of
the small intestine, the extreme environmental
conditions result in it having a lower microbial density.
In the distal part of the small intestine, near the ileum,
these conditions become less limiting. Microbial density
is highest in the colon where the transit time is slower,
and the absence of easily digestible nutrients facilitates
the proliferation of fermentative organisms that are able
to degrade more complex compounds, including dietary
fiber. These organisms include, for example, representa-
tives of the Bacteroidetes (Bacteroidaceae, Prevotella-
ceae and Rikenellaceae) in the lumen and Firmicutes
(Lachnospiraceae and Ruminococcaceae) in the inter-
fold regions.16
Despite the fact that bacteria have been most exten-
sively studied, there are other groups of microbes in the
human GI tract that have not been as well researched
but have an important role in the ecological dynamics,
like archaea, viruses and eukaryotes.10,20 Archaea is rep-
resented by Euryarcheota and Crenarchaeota.Methano-
brevibacter smithii has been identified as the dominant
human methanogen where it is estimated to be present
in 50% of the adult population21 and the concept of
archaebiotics has been proposed, as probiotics of
archaeal origin.22 Eukarya presence includes amoebae
and fungi. The concept ‘mycobiome’ has been proposed
to cover the diversity and dynamics of fungi in the
human body.23 It has been suggested that mycobiome
and microbiome are intimately regulated, influencing
each other in the colonization of the gut niche and hav-
ing a crucial effect on the overall health status of the
host. Recent reviews describe the human mycobiome
and its implications in health and disease.24,25 “Virome”
is another recent concept to define the community of
viruses that can be found within the human host.26
There are also eukaryotic viruses, plant derived viruses
that have a dietary origin, giant viruses and bacterio-
phages.26 Antimicrobials produced by representatives of
these groups in the gut have not been identified and
characterized yet, to the best of our knowledge. How-
ever, Archaea, Eukarya and viruses are already known
for their antimicrobial capabilities. Fungi are an espe-
cially important source of antibiotics27 and Archaea
have also been reported to show antimicrobial activ-
ity.28,29 Some bacteriophages produce lytic enzymes that
can kill bacteria,30 and the use of the phages derived
from the human gut has been proposed as a potential
therapeutic to modulate gut composition (phage ther-
apy).26,31 Further examination of these groups might
reveal novel antimicrobials andmodulation strategies.
3. Non-peptide antimicrobial activity in the gut
Bacteria develop different antagonism strategies to gain
ecological advantages over other bacteria in the gut.
Some of them are direct strategies, like competitive
removal of essential substrates, accumulation of D-
amino acids, lowering the oxidation-reduction potential
and co-aggregation.32 Another strategy involves the pro-
duction of substances of metabolic origin that have the
ability to limit the growth of surrounding bacteria. Such
activity can be specific or non-specific, where the regula-
tory agent does not address a specific target, hydrogen
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peroxide (H2O2) being a good example of a chemical
with such activity. H2O2 is well known for its antimicro-
bial properties that are mediated through oxidizing
effects on bacterial cells and their molecular structures.33
It has been suggested that H2O2 contributes to maintain
a healthy microbiota.34 H2O2 can function synergisti-
cally with other compounds produced by bacteria, such
as lactic acid,35 but its presence has also been linked to
chronic inflammatory lesions in colon.36 Lactic acid and
other organic acids are believed to function by virtue of
their undissociated form crossing the lipid membrane
and its subsequent dissociation in the neutral pH once
inside, producing ions that cause stress in the cell. Lactic
acid is produced by the carbohydrate metabolism of the
so called lactic acid bacteria (LAB), while the important
group of short chain fatty acids (SCFA), such as formate,
acetate, propionate and butyrate, are produced by bacte-
ria fermenting starches, dietary fiber, sugars, proteins
and amino acids37 and their antimicrobial activity is due
to acidification of the environment.38 There are other
compounds of bacterial origin, like diacetyl (2,3-buta-
dione),39,40 ethanol, CO2, ammonia or phenolic
compounds, which have also been associated with anti-
microbial activity,11 but, as with the previous examples,
their non-specific activity and other side effects,41 make
them unsuitable for clinical applications and they will
not be discussed further in this review.
4. Peptidic antimicrobial activity in the gut
Bacteria are also capable of producing antimicrobial
peptide compounds that are considered to be target-spe-
cific. Peptides with antimicrobial properties are classified
based on their biosynthesis, which can be ribosomal or
non-ribosomal. In general, antimicrobial peptides con-
sist of 10–50 amino acids and their ability to kill bacteria
depends on their interaction with bacterial membranes
and cell walls. Selectivity depends on membrane or cell
wall composition.42 The levels of production and accu-
mulation of these compounds in the gut depend on the
producer strains, their chemical structure, bioavailability
and physical conditions within the surrounding environ-
ment, making the identification and direct isolation of
those compounds difficult. Recently, a bioinformatics
tool, ClusterFinder, has been used to identify thousands
of biosynthetic gene clusters from human metagenomic
samples, encoding among other compounds, antimicro-
bial peptides, highlighting the potentially underexploited
therapeutics derived from the humanmicrobiome.43,44
4.1. Non-ribosomal peptides (NRPs)
NRPs are secondary metabolite peptides synthesized
by multienzyme complexes of multifunctional peptide
synthetases.45 NRPs constitute a large class of bacterial
products in several environments and their study has
provided many of the antibacterial compounds cur-
rently in use, such as penicillins, vancomycin or
polymyxin that are considered as peptide derived.45
However, there are very few NRPs characterized from
the human microbiota.11 Although analysis of the
Antimicrobial Peptide Database (APD3) did not show
any NRPs of human gut origin,29 Donia and Fisch-
bach listed some NRPs that had been characterized
from bacterial producers isolated from the human
microbiome.11 The peptides cereulide, zwittermicin
and tilivalline were isolated from pathogens from the
human gut although they are not normally present in
human gut microbiome.11 Their activity is described
as cytotoxic, alongside with colibactin activity, pro-
duced by Escherichia coli.46 Zwittermicin activity has
been reported as antimicrobial47 but resistance genes
for it have also been identified.48 Therefore, the use of
such NRPs as therapeutics would be limited.
4.2. Ribosomally synthesized peptides (Bacteriocins)
Bacteriocins are ribosomally synthesized peptides that
exhibit antimicrobial activity. The first bacteriocin was
discovered by Gratia in 192549 and named “colicin”.
Since then, many more bacteriocins have been isolated
and characterized, mostly based on their bioactivity, in a
wide variety of environments and from many different
bacterial species. Bacteriocins have been proposed as
mediators in population dynamics and their ecological
role in this regard has been studied in recent
decades.5, 50, 51 A considerable number of these peptides
have originated from bacterial isolates from foods,
though many important bacteriocins are produced by
bacteria that inhabit theGI tract of humans and animals.
Indeed, given the density and diversity ofmicrobial pop-
ulations present in the gut, it may represent a source of
bacteriocin producers that is, as yet, relatively underex-
plored. Bacteriocins address some of the problems
described for traditional antibiotics and that is why their
range of applications is expanding towards human and
veterinary therapeutics.52,53 They have low toxicity,
making them suitable for use as food and beverage pres-
ervatives, since traditional antibiotics are prohibited for
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use in foods. Low toxic effects have been proven for
many of the bacteriocins in different studies,54,55
although a small percentage have shown some cytotoxic
activity.56 Bioinformatics is also helping to identify puta-
tive anti-tumoral activity of bacteriocins, as has been
described recently.57,58 Antiviral and antifungal proper-
ties of bacteriocins represent other potential application
of these peptides.59,60
Some bacteriocins can exhibit broad-spectrum while
others exhibit narrow-spectrum antimicrobial activity.
The former have the possibility of being used as a tradi-
tional therapeutical antibiotic, while the narrow spec-
trum antimicrobials are more suitable for targeting
specific harmful microorganisms without altering the
natural populations,61 contributing to maintaining a
balance in microbial populations. As a general rule, bac-
teriocins produced by Gram-positive bacteria show bet-
ter activity against Gram-positive pathogens and Gram-
negative bacteriocins work better on Gram-negative
pathogens, but with purified bacteriocins and bioengi-
neered derivatives it has been possible to cross this bar-
rier.62 Furthermore, their activity can be enhanced by
the presence of other substances, such as lactic acid, that
allows the permeabilization of the bacterial membrane.
One of their most attractive features is that resistance is
not easily developed against them. In order to do that,
target cells would have to alter membrane composition63
or the receptors.64,65 Transporters have also been
pointed as a mechanism to develop resistance,66 and
although they are not very common, expression of resis-
tance proteins have also been reported.67,68 Bacteriocin
combination or using strains that produce more than
one, in order to maximize efficacy is another possibil-
ity,69 and they can also be combined with other com-
pounds to act synergistically.70,71 In addition, bioactivity
is in a nano- to micromolar range, while an absence of
taste, color or odor, makes them suitable for industrial
and clinical purposes.63
Another asset of such peptides is that they offer the
possibility of being bioengineered, either by gene manip-
ulation or partial or complete chemical synthesis, to
improve properties such as specific activity, stability and
host range. Rational design might be the key to obtain
more potent bacteriocins, based on the structure-func-
tion relationship;72 and bacteriocins could be modified
to have broader activity against new pathogen targets,62
or narrowed activity to target specific pathogens, to treat
biofilms and resistant bacteria,73,74 or increase protease
resistance against chymotrypsin or trypsin, which can
aid their survival in the gut. Key residues have been
identified, along with the mechanisms that control activ-
ity and regulation that have been studied using natural
variants and the generation of peptide derivatives.75
Delivery matrices have been examined to maintain bac-
teriocin stability and in this regard, nanotechnology has
been used as one of the most important approaches,
with the use of nanoliposomes or nanoparticles of differ-
ent composition.76 Improvement of delivery strategies
might offer new therapeutic possibilities for bacteriocins,
like new targets or controlled delivery.77,78
4.2.1. Identification of bacteriocins
Identification of new bacteriocins originally relied on
methods to identify antimicrobial or antagonistic activ-
ity of a bacterial strain on a target bacterium. Bioassays
for detecting inhibitory activity can present variations
for adapting to specific needs.79 One technique is to
inoculate media with the specific indicator strain and
add a spot of the bacteriocin producing strain or its cell
free supernatant (spot test). A common variation is the
growth on agar of the producer strain and subsequent
overlay with indicator-inoculated soft agar (overlay
assay). In both cases the activity is estimated by the
inhibition of growth of the indicator strain (Fig. 1).
Well diffusion assays and disc assays both involve
placement of the cell free supernatant of the producer
strain in a well or on a paper disc in indicator inocu-
lated agar followed by incubation, with the bacteriocin
producing a zone of inhibition which can be used to
measure specific activity (Fig. 1).79 The indicator strain
can also be co-cultured with the producer strain or its
supernatant and growth assessed by measurement of
optical density.80 Despite the extended use of these
techniques and their variations, this approach has a
limitation, as just a small percentage of bacteria are
able to grow in culture and in vitro growth may not
provide the appropriate conditions to induce the bio-
synthesis of bacteriocins.81 Some of the bacteriocin-like
compounds identified required the presence of a trigger.
For example, the presence of trypsin has proven to be
effective as an antimicrobial inducer in human gut iso-
lates,82 and both cell density and carbon source were
necessary to induce bacteriocin production in Strepto-
coccus pneumoniae,83 reinforcing the idea that the envi-
ronment plays an important role in the production of
these compounds. Understanding all the factors and
interactions that take place in the environment of the
potential producing bacteria and the development of
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strategies to mimic these interactions can be a gargan-
tuan task. A recently developed peptidogenomics strat-
egy attempts to establish a mass spectral molecular
network of microbes grown in a plate and integrate
this information with genomic and phenotypic infor-
mation.84 This could be a good first step towards a
holistic approach to microbial interactions that could
lead to the identification of novel compounds produced
from these simultaneous and multilateral interactions
in a more realistic and complex environment such as
the GI tract.
The development of molecular tools removes the
requirement for functionality influenced by culture con-
ditions and induction. This has allowed the identifica-
tion of putative bacteriocin clusters in genomes, both in
culturable and unculturable species. There are public
software and databases to identify putative bacteriocin
clusters in sequenced genomes and also offer access to
bacteriocin peptide sequences. BAGEL with 482 sequen-
ces85 and BACTIBASE with 345 sequences86 are the
most commonly used. Broader databases are available to
screen for potential new bacteriocin clusters in the gut,
like the Human Microbiome Project’s reference genome
database.87,88 An analysis of this database by Walsh et al
identified 74 putative bacteriocin-encoding gene clusters
in different phyla.87 A more accurate analysis of the dis-
tribution and frequency of specific bacteriocin types can
be addressed by the use of Hidden Markov Model, as
performed for LanB homologues, allowing the identifi-
cation of seven new lantibiotic producers.88 Drissi et al
developed an extensive database for bacteriocins, BUR
(“Bacteriocins of the URMITE database”), where they
combined BAGEL, BACTIBASE and NCBI databases
for bacteriocin published sequences and also retrieved
641 available genomes from the GI tract that they ana-
lyzed in order to incorporate as much bacteriocin data
as possible.89 The study of this database provided some
interesting observations. First, it showed differences
between bacteriocins produced by gut bacteria and bac-
teria from other environments. These differences were
found in the amino acid composition and peptide
length, with those for gut bacteria generally being
shorter and having less positively charged and less
hydrophobic residues, lower percentages of aspartic
acid, leucine, arginine and glutamic acid, and higher per-
centages of lysine and methionine.89 The most predomi-
nant class was class I, with 44% of bacteriocins
produced in the gut, while class III was less represented
(17.3%). This is also a significant difference with bacter-
iocins from other environments, where class III repre-
sents 59.2% and class I only 13%. Different bacterial
groups generate different classes of bacteriocins: Actino-
bacteria (58%), Proteobacteria (94%) and Bacteroidetes
(exclusively) were identified mainly as producers of class
III bacteriocins, while Firmicutes showed production of
bacteriocins of all classes more evenly (20% class I, 45%
class II and 35% class III).89
In Tables 1, 2 and 3 we have compiled the known
bacteriocins isolated from the human gut based on the
analysis of BAGEL3, BACTIBASE and APD3 databases.
4.2.2. Classification of bacteriocins
Due to the heterogeneous nature of the bacteriocins,
there have been different criteria to classify them (e.g. by
primary structure, molecular weight, mode of action,
heat stability, genetic properties). Currently the most
accepted is that based on their structure. This review will
follow the classification scheme proposed by Cotter
et al,56 to highlight the diversity of bacteriocins produced
bymembers of the gut microbiota. Examples of bacterio-
cin structures and gene operon organization are shown
in Figs 2 and 3.
Figure 1. Examples of assays performed to identify antimicrobial activity. (a) spot test; (b) overlay; (c) well diffusion.
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Microcin M E. coli Nissle 1917 E. coli, Salmonella 151
Microcin V
(ColicinV)
E. coli E. coli 49
Microcin H47
(MccH47)
E. coli H47 E. coli, Salmonella, Enterobacter,
Shigella, Klebsiella, Proteus spp.
152





Lasso peptide Lasso knot structure Microcin J25 E. coli AY25 E. coli, Salmonella sp, Shigella flexneri 96
Sactibiotics Sulphur-a-carbon linkages Thuricin CD Bacillus thuringiensis DPC
6431




Lantibiotics Lanthionine bridges Ruminococcin A Ruminococcus gnavus Bacteroides sp, Clostridium sp,
Bifidobacterium sp, B. cereus
116





Enterococcus faecalis Gram-positive bacteria 114





Heterocycles but no other
modifications
Microcin B17 E. coli Nissle 1917 E. coli, Salmonella, Shigella 151
Examples of Class I (Linardins, Proteusins, Patellamide-like cyanobactins, Anacyclamide-like cyanobactins, Thiopeptides, Bottromycins and Glycocins) have not yet
been described from human gut isolates. Classification of bacteriocin is based on Cotter et al, 2013.
Table 2. Class II bacteriocins produced by bacteria originally isolated from the human gut.







isolated from human Activity against Reference
IIa peptides (pediocin PA-
1-like bacteriocins)
Conserved YGNGV motif (N
represents any amino acid)
Bac43 Enterococcus faecium
VRE82
E. faecalis, E. faecium, Enterococcus
hirae, Enterococcus durans, and L.
monocytogenes
122
Bacteriocin RC714 E. faecium strain RC714 E. faecalis, E. faecium, L.
monocytogenes, Listeria innocua,
Listeria murrayi, Listeria grayi,
Lactobacillus paracasei, Lactobacillus
plantarum, Leuconostoc sp., and
Pediococcus pentosaceus
124
Bacteriocin 31 E. faecalis YI717 E. hirae 9790, E. faecium, and L.
monocytogenes
155





Acidocin J1132 Lactobacillus acidophilus
JCM1132
Lactobacillus sp 126





Lactacin F Lactobacillus johnsonii Lactobacillus sp, E. faecalis 156
IIc peptides Cyclic peptides Gassericin A L. gasseri LA39 Bacillus, Clostridium, Lactobacillus spp,
Lactococcus lactis, Leuconostoc
mesenteroides, Listeria spp,
Pediococcus cerevisiae, S. aureus,
Streptococcus agalactiae
157
Reutericin 6 Lactobacillus reuteri LA 6 L. acidophilus, L. delbrueckii subsp.
bulgaricus and L. delbrueckii subsp.
lactis
158
AS-48 E. faecalis AS-48 Gram-positive and Gram-negative 159
IId peptides Unmodified, linear, non-pediocin-
like, single-peptide bacteriocins
Microcin S E. coli G3/10 E. coli G3/10 136
Rhamnosin A Lactobacillus rhamnosus
strain 68
Micrococcus lysodeikticus ATCC 4698 138
Bac32 Vancomycin-resistant E.
faecium (VRE) 200
E. faecium, E. hirae, and E. durans 139
Examples of Class II (IIe) have not yet been described from human gut isolates. Classification of bacteriocins is based on Cotter et al, 2013.
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4.2.2.1. Class I bacteriocins. This class contains dif-
ferent subgroups, which are all small heat-stable peptides
of less than 10 kDa and share the process of enzymatic
modification during their biosynthesis. The use of char-
acteristic amino acids and structures is distinctive and
will have an influence on their future function. The most
studied group is lantibiotics, but the development and
implementation of more accurate and advanced techni-
ques is broadening our understanding of other modifica-
tions discovered more recently. Here we discuss the
subgroups of this peptide class whose producers were
isolated initially from the human gut microbiota.
4.2.2.1.1. Microcins. Microcins are peptides produced
by Enterobacteriaceae90 (Fig. 2). They are differenti-
ated from colicins, also produced by Enterobacteria-
ceae, by their smaller molecular mass (microcins are
smaller than 10 kDa, while colicins are larger than 20
kDa). Microcin operons are constituted by genes
encoding a precursor, secretion proteins and elements
for self-immunity (Fig. 3). Microcins are subdivided
in two groups, based on molecular masses and pres-
ence of disulphide bonds and post-translational modi-
fications.90 Thus, class I microcins are encoded
on plasmids, smaller than 5 kDa and have extensive
post-translational modifications. Class II microcins
(between 5–10kDa) can be further classified into class
IIa, encoded by plasmids, with one, two or no disul-
phide bonds and no post-translational modifications,
and class IIb, encoded on chromosomes and a non-
mandatory post-translational modification.90 They are
considered to be hydrophobic and have heat, pH and
protease stability.91 Microcins are known for having a
precursor peptide that needs to be cleaved during their
transport from the producer cells.92 Currently there
are at least 16 microcins identified, but only eight of
them have been characterized structurally.92 The
mode of action of microcins is described as a “Trojan
horse”,90 mimicking essential compounds for nutri-
tion, for example an iron-siderophore complex, that
the target cell will detect using outer-membrane recep-
tors and will incorporate. They can also be secreted as
a non-active compound and be processed to the
bioactive form by the target cell. Once inside the cell,
microcins bind enzymes or interact with the inner
membrane.90,93
4.2.2.1.2. Lasso peptides. These were first described in
1991 by the discovery of anantin.94 They are RiPPs of
bacterial origin characterized by their distinctive
structure as a knot, including a macrolactam ring
crossed through by the C-terminal tail. This structure
is sustained by steric interactions and disulphide
bridges and it is very stable. There are three classes of
lasso peptides described so far, and the criterion fol-
lowed is the number of disulphide bridges: class I has
two disulphide bonds, class II no bonds and class III
just one.94 They have been reported to have inhibitory
activity against enzymes, receptor antagonistic behav-
ior and a few of them display antimicrobial activity.95
Although during the first years their discovery was
activity-based, increased application of genome min-
ing has resulted in a rapid increase of discovery of
lasso peptide biosynthetic gene clusters. In a recent
review by Heggeman et al95 a total of 38 known lasso
peptides were identified. Currently almost all lasso
peptides have been isolated from soil, sludge and
water bacteria,95 with the exception of zucinodin, iso-
lated from an erythroleukemia cell line, and microcin
J25, isolated from baby feces.96 They have also
attracted attention because they have been proposed
to be used as new chemical scaffolds, due to their
stability.
Microcin J25 is the paradigm of lasso peptides and
has been studied as a typical example of its class. It
has 21 amino acids and is produced by E. coli AY25
that was isolated from newborn feces. Typically, it
forms a ring by a lactam linkage between the first gly-
cine and the glutamate at position 8 (Fig. 2B). The
remaining thirteen residues form the tail, with the
phenylalanine in position 19 and tyrosine at position
20 acting as plugs.97 The biosynthetic cluster has four
genes: a precursor (mcjA), cleavager of leader peptide
(mcjB), a macrolactam ring formation gene (mcjC)
and a gene that encodes the ATP-binding cassette
transporter (mcjD) (Fig. 3). Despite their genomic
Table 3. Class III bacteriocins produced by bacteria originally isolated from the human gut.
Class III
Group Distinctive feature Bacteriocin from human gut isolate Gut Producer first isolated from human Activity against Reference
Bacteriolysins Colicins E. coli Enterobacteria 49
Bacteriocin 28b Serratia marcescens E. coli 141
Non-lytic bacteriocins Bacteriocin helveticin J L. acidophilus NCFM 142
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identification, biosynthesis of lasso peptides has not
been fully elucidated.98 MccJ25 antimicrobial activity
is based on inhibiting the RNA polymerase of Gram-
negative bacteria but another activity has been
described, depolarizing cell membranes in Salmonella
and E. coli species that overexpress fhuA.95
Figure 2. Examples of bacteriocin structures. (a) nisin A1, lantibiotic160; (b) microcin J25, lasso peptide161; (c) microcin E-492, microcin162;
(d) thuricin CD subunits, sactipeptide154; (e) microcin B17, linear azole or azoline containing peptides163; (f) enterocin NKR-5-3C1, class
IIa164; (g) lactococcin Q1, class IIb164; (h) lactocyclicin Q1, class IIc164; (i) lacticin Q1, class IId164; (j) colicin A1, class III.49 1Note that these
bacteriocins have not been described as of human gut origin.
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4.2.2.1.3. Sactibiotics. Sactipeptides are a general group
of peptides characterized by having an intramolecular
bridge between a cysteine sulphur and an a-carbon and
do not always show inhibitory activity; the term sactibi-
otic is used to describe sactipeptides with antimicrobial
activity. Many of them have been identified by genome
mining99 and currently there are four sactibiotics
described: subtilosin A, propionicin F, thuricin H and
thuricin CD.100 Among them, only thuricin CD has
been isolated from a bacterium from the human gut.
Produced by Bacillus thuringiensisDPC6431, it is partic-
ularly important because it has been shown to have very
specific activity against Clostridium difficile, Bacillus
cereus, Bifidobacterium firmus and Listeria monocyto-
genes.101 It is composed of two subunits, Trna and Trnb
(Fig. 2D). Its gene cluster contains structural genes,
transport, immunity and post translational modification
genes (Fig. 3). The presence of genes encoding members
of the radical S-adenosulmethionine superfamily of pro-
teins is also a specific characteristic. Thuricin CD’s
mode of action has just started to be elucidated. Mathur
et al showed that both subunits act on the cell mem-
brane, irreversibly collapsing the membrane potential
and suggested that the peptides are inserted in the mem-
brane of the cell, forming a pore that leaks ions and ulti-
mately leading to cell lysis.102 The effect of thuricin CD
was similar to vancomycin andmetronidazole, both rou-
tinely used to treat C. difficile infections.
4.2.2.1.4. Linear azole-or azoline-containing peptides.
These peptides, also called LAPs, are characterized by
presenting different combinations of heterocyclic
rings of thi-azole and (methyl)oxazole. These are pro-
duced by a cyclodehydration of cysteine and serine or
threonine, and a flavin mononucleotide dependent
dehydrogenation reaction.103 Their mode of action is
not yet fully understood. Microcin B17 is a LAP pro-
duced by E. coli isolated from baby feces104 (Fig. 2E).
Its cellular target is the DNA gyrase and it has been
extensively studied to discover the link between its
structure and function, in order to obtain information
to design new antimicrobials.105 There is an increasing
interest in studying the inhibition of topoisomerases
and gyrases as targets for designing antimicrobials,
and the study of microcin B17 can offer further
insights into the structure and functional analysis of
this antimicrobial target.106 In vivo studies have
already demonstrated their ability to control infections
in infants107 and cattle.108
4.2.2.1.5. Lantibiotics. The term “lantibiotic” comes
from “lan-thionine containing antibiotic”. Similar to
sactibiotics, lantibiotics are embedded in a bigger
group, lantipeptides, not all of which show antimicro-
bial activity. This subgroup is constituted by small
peptides (<5 kDa) with presence of modified amino
acids such as dehydroalanine (Dha) and dehydrobu-
tyrine (Dhb), among others.109 Dha and Dhb are
derived from the dehydration of Ser and Thr residues
respectively, the process followed in order to obtain
2,3-didehydroalanine and (Z)-2,3-didehydrobutyrine;
an additional modification is the stereospecific intra-
molecular addition of a cysteine residue to form
Figure 3. Examples of bacteriocin cluster organization among the
different bacteriocin classes. Genes are colored according to the
function of their products: red, precursor peptides; green, post-
translational modifications; blue, export; yellow, immunity; pink,
regulation; purple, export and immunity; orange, lysis; grey,
unknown function. Class I: microcin J2591; nisin A109; microcin E-
49291; thuricin CD100; microcin B1791; class IIa bacteriocin 43122;
class IIb ABP-118127; class IIc AS-48165; class IId microcin S137; class
III colicin.49
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lanthionine (Lan) or methyllanthionine (MeLan)
bridges. In total up to 17 uncommon amino acids
have been described.110 The function of these modified
amino acids is not known, but it has been suggested
that they interact with free sulfhydryl groups on the
cell envelopes of target organisms.109
Genes encoding lantibiotics are organized in clus-
ters which are often highly conserved and have similar
functions. A basic lantibiotic cluster contains genes
for a precursor peptide, known as LanA, modification
enzymes (LanB and LanC or LanM), usually a prote-
ase to remove the leader peptide (LanP); an ABC
transporter (LanT) that translocates the peptide and
sometimes also encodes the protease activity; a two-
component regulatory system (LanR and LanK), and
proteins responsible for self-immunity (LanI and Lan-
FEG) (Fig. 3). Defined steps in the production and
maturation of lantibiotics involve synthesis of the
prelantibiotic, dehydration and linkage reactions,
removal of the leader sequence, and secretion.
Depending on the enzymes present during the matu-
ration process four groups have been differentiated:
class I, LanBC-modified (involves LanB, with dehy-
dratase function and LanC, a cyclase); class II, LanM-
modified (LanM encodes both dehydratase and
cyclase functions); class III uses LanKC and class IV
uses LanL, but only class I and II show antimicrobial
activity.111
The most common mechanism of action of lantibi-
otics is through lipid II binding. Lipid II plays an
important role in the formation of cell wall and inter-
fering with its function is fatal for the cell. The two
ways of disrupting the cell wall are by inhibiting its
synthesis or by pore formation.111 Nisin, the most
studied lantibiotic (Fig. 2A), has both functions, but
not all lantibiotics have the same mode of action. This
activity on the cell wall is the reason that lantibiotics
are not very effective on Gram negative bacteria, due
to their outer membranes that present a barrier for
entry to the bacterial cell wall. It has been a common
belief that lantibiotics are only produced by Gram-
positive bacteria, but the recent identification of pine-
nsins, lantibiotic type bacteriocins produced by the
Gram-negative bacteria Chitinophaga pinensis, that
also show antifungal activity,112 is an example of how
broad metabolic diversity is and that there are func-
tions still to be discovered. At the moment, the front
line in lantibiotic research is focused on the transfer-
ence of the in vitro efficacy to in vivo tests, and the use
of bioengineering to improve mode of action and effi-
ciency of delivery systems.113 There are many lantibi-
otics that are being tested in vivo for a variety of
health applications, especially targeting bacteria of
clinical relevance, and some are now in pre-clinical
development.113
Some of the lantibiotics that can be found in the
human gut are synthesized by gut pathogens, like the
two-component cytolysin, produced by Enterococcus
faecalis.114 This cytolysin is one factor contributing
to its virulence and facilitates antibiotic resistant
infections,115 and it is highly efficient against other
Gram-positive bacteria. Cytolysin is composed of two
subunits, large (L) and small (S); the gene cluster also
encodes proteins for post translational modification,
export, and a protease for activation and immunity.
Its activity is regulated by a two-component system
that functions via quorum-sensing autoinduction.
The products of two genes, cylR1 and cylR2, repress
transcription of the bacteriocin components so that
production is low. When cell density increases, the
small subunit of cytolysin reaches levels high enough
to overcome the repression and induce transcription
of the bacteriocin components.114 Other lantibiotics
are produced by commensal gut microbes. Rumino-
coccin A, produced by Ruminococcus gnavus, was the
first characterized bacteriocin from a strict anaerobe
isolated from a human fecal sample and requires
trypsin for antimicrobial activity,116 while genomic
analysis of B. longum DJO10A identified the presence
of a novel lantibiotic gene cluster with activity against
a related strain.117 Recently, a new variant of nisin
(nisin O), has been identified from the human gut
bacterium B. obeum A2-162.118 This showed activity
against important gut pathogens C. difficile and C.
perfringens.118
4.2.2.2. Class II bacteriocins. Class II constitutes the
most extensive group of bacteriocins. They are charac-
terized by being small heat stable peptides (<10 kDa)
that do not undergo post translational modifications.
According to their specific relationships between
structure and function, they can be classified into four
subgroups. There have been different criteria to the
establishment of these subgroups. Here we will use the
one proposed by Cotter et al.56
4.2.2.2.1. Class IIa. Also known as pediocin-like bac-
teriocins, these contain an N-terminal consensus
sequence YGNGVXaaCXaaK/NXaaXaaC which is
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highly conserved (Fig. 2F). This includes the “pediocin
box” (YGNGV). They are characterized also by having
two cysteines in the conserved region which form a
disulfide bond required for antimicrobial activity.119
The C-terminus is responsible for specificity and their
mode of action is via permeabilization of the bacterial
cell wall. The sugar transporter mannose phosphotrans-
ferase system (Man-PTS) is the target receptor, present
in Gram-positive and Gram-negative bacteria,120 and
they have particularly strong activity against Listeria
spp.119 Biosynthesis of the peptide commonly requires
at least four genes: a structural gene encoding a precur-
sor, and the genes encoding an immunity protein, an
ATP-binding cassette transporter and a protein for
extracellular translocation. They are regulated by quo-
rum sensing, and the regulatory system is composed of
three genes, encoding an inducer peptide, a membrane
associated histidine protein kinase, and a cytoplasmic
response regulator.121 Bacteriocin 43 was isolated and
characterized from a vancomycin-resistant clinical iso-
late Enterococcus faecium (VRE). Its sequence showed
high homology with bacteriocin 31 from E. faecalis
YI717 and bacteriocin RC714 from E. faecium strain
RC714,122 both clinical isolates too.123,124 It is unusual
in requiring only 2 genes, one structural and one for
immunity122 (Fig. 3).
4.2.2.2.2. Class IIb. This class is represented by bacter-
iocins that need two different peptides to act synergisti-
cally in order to exert their antimicrobial activity125
(Fig. 2G). Normally their genes are located on the same
operon and they are expressed simultaneously (Fig. 3).
The killing mechanism involves membrane permeabili-
zation. The peptides that constitute the bacteriocin have
similar characteristics to one peptide bacteriocins, being
usually cationic and hydrophobic or amphiphilic, with
a length of 30 to 50 amino acids. Their synthesis
includes a double-glycine leader type sequence in the N
terminus that it is cleaved off during secretion of the
peptide to the outside of the cell.
A range of bacteriocins of this class originating from
bacteria of human gut origin are identified in BAGEL3,
BACTIBASE and APD3 databases. Acidocin J1132 was
produced by from L. acidophilus JMC 1132, isolated
from human feces;126 it was found that its production
relied on the pH of the medium not being above 7,
with maximum production at pH 5. The mode of
action against other taxonomically close strains showed
a bactericidal activity.126 ABP-118 was the first bacterio-
cin to be isolated and characterized from a bacterium
that was already considered a probiotic.127 L. salivarius
UCC118, isolated from the ileal-caecal region of the
human GI tract was proven to produce ABP-118 in
vivo and it has been tested in order to assess its poten-
tial activity, resulting in the control of L. monocytogenes
infection in mice.128 Its activity has also been tested as
a gut microbiota regulator, leading to population shifts
by increasing Bacteroidetes and Proteobacteria and
decreasing Actinobacteria.129
Gassericin T is another representative of this class.
Produced by L. gasseri SBT 2055 isolated from human
faeces, it is part of the lactacin F family, sharing a 60%
similarity with lactacin F.130 Lactacin F, another class
IIb bacteriocin produced by a gut bacterium, requires
two hydrophobic peptides LafA and LafX for its anti-
microbial activity and it has been shown to be effective
in combination with nisin.131
4.2.2.2.3. Class IIc. These are cyclic peptides that
contain a covalent bond between the C and N termini
(Fig. 2H). They are generally cationic and have some
degree of hydrophobicity. Initially their mode of
action was identified as disruption of the cell mem-
brane allowing permeabilization of the bacterial cell
membrane to small molecules, leading to cell death.
However, inhibition of nucleic acid, protein, cell wall
synthesis and enzyme activity have also been reported
as additional mechanisms of inhibition.132 Their struc-
ture is believed to confer a 3-dimensional stability and
makes them more resistant to proteolysis.
Some bacteriocins of human gut origin could be
found in the databases. Among them, the paradigm of
a circular bacteriocin is considered to be AS-48, an
a-helical and cationic peptide first isolated from E.
faecalis. It is extensively distributed among different
Enterococcus species from clinical to food isolates, and
a number of different derivatives, both engineered and
natural are available (e.g., AS-48J, isolated from goat
cheese133). It maintains stability and solubility through
a broad range of pH and temperature, and the most
attractive feature is its broad spectrum of activity,
affecting both Gram-positive and Gram-negative bac-
teria. Its applications as a food preservative is well
documented, but new functions arise from the imple-
mentation of new strategies, like liposome-encapsula-
tion.134 The successful treatment against S. aureus
from bovine mastitis opens the possibility of veteri-
nary applications. Other applications being investi-
gated include its use as a leishmanicidal agent135 or
against bacterial biofilms.134
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Gassericin A is produced by an isolate from the
human gut L. gasseri LA39. It has the same primary
amino acid sequence as reutericin 6 produced by L. reu-
teri LA6, both isolated from feces of the same baby,132
but differs in one D-alanine residue, which confers on
gassericin A a broader spectrum of activity. In fact, gas-
sericin A can inhibit the growth of L. reuteri LA6, but
not the other way around. The activity of reutericin 6 is
also influenced by the presence of substances on the sur-
face of the target cells and low pH values, highlighting
once more the importance of the secondary and tertiary
structures of bacteriocins and the close relationship
between this and the mode of action and efficacy.
4.2.2.2.4. Class IId. These are unmodified, linear,
non-pediocin like, single peptides (Fig. 2I). This group
was proposed as a miscellaneous collection to group
different bacteriocins of class II that did not fit else-
where. There were a few representatives of this class
identified from human gut in databases. Microcin S is
a bacteriocin produced by E. coli G3/10 that is part of
the probiotic marketed as Symbioflor, constituted by
six different E. coli genotypes, and used for gastroin-
testinal disorder treatments, especially intestinal bowel
syndrome (IBS).136 Microcin S inhibits the adhesion of
the enteropathogenic E. coli E238/6 to intestinal epi-
thelial cells.137 Rhamnosin A138 and Bac 32 were also
assigned to this subclass of bacteriocins.139 Bac 32 is
encoded by a plasmid and has been identified as pres-
ent in a wide number of clinical isolates of E. faecium,
having a narrow sprectrum of action that only
includes other Enterococci.139
4.2.2.3. Bacteriocins class III. These are large (> 30
kDa), heat-labile proteins, usually with different
domains (Fig. 2J). Bacteriocins of this group are not
very well characterized. They are classified into two
groups depending on their mode of action: class IIIa
or bacteriolysins, which lyse the cells, and class IIIb or
non-lytic bacteriocins, which disrupt the membrane
potential. Colicins are the most important type of bac-
teriocin representing class IIIa.49 The first colicin
(colicin V) was originally isolated from E. coli, and is
now classified as a microcin, but many colicins have
been isolated from other enteric bacteria. They have a
narrow spectrum of action and they act by binding to
specific receptors on the surface of the target cells.
They have different modes of action: inhibiting mac-
romolecular synthesis, causing DNA breakdown and
stopping protein synthesis. Colicins can be further
divided into two subgroups based on their encoding
plasmids: group A are on small plasmids and excreted
and group B are encoded by large plasmids and are
not excreted, although some of them have mixed char-
acteristics. Colicin operons are formed, as a general
trend, by a structural gene, an immunity gene and a
lysis protein gene. Bacteriocin 28b, isolated from
many biotypes of Serratia marcescens also belongs to
class III. Its structural analysis showed similarities to
colicins and it is active against E. coli.140 The different
biotypes of S. marcescens that produce bacteriocin 28b
were clinical isolates, driven by a study of nosocomial
infections caused by this bacterium.141 A helveticin J
bacteriocin has also been identified from the genome
of L. acidophilus NCFM, a probiotic strain that is
widely commercialized.142
5. Applications of gut produced antimicrobials
The use of broad spectrum antibiotics has associated
problems of increasing antibiotic resistance and con-
comitant disturbance of the beneficial commensal
microbiota. Natural antimicrobials produced by bacte-
ria from the human GI tract are attracting interest in
their potential to offer specific solutions to health
problems. Bacteriocins can be considered not only as
antimicrobials but also, when produced in a mixed
microbial community, as regulatory elements to bal-
ance the ratio between desirable and undesirable bac-
teria, offering competitive advantage to beneficial
bacteria against bacteria that cause dysbiosis. In an
effort to establish the microbiota alterations associated
with certain pathologies, correlations between propor-
tions and presence or absence of certain bacterial
groups and functionality have been studied. This has
revealed dysbiotic relationships between gut micro-
biota and host pathologies. The disruption of the bal-
ance of the microbiota in the gut has been associated
with metabolic disease, type 2 diabetes, colorectal can-
cer or IBD.50 Rational application of bacteriocins,
either directly or produced by bacteria in situ as probi-
otics, is being studied as a method to modulate the
structure and function of the gut microbiota and to
control these acute and chronic pathologies. Guinane
and Cotter (2013) summarized the microbial associa-
tions with chronic intestinal diseases.15 Others focus
on the probiotic use of bacteriocins and their use to
modulate the gut microbiota.143 A strategy of produc-
tion of many bacteriocins with low activity and a few
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specific highly active antimicrobials points towards a
functionality focused on maintaining homeostasis and
providing defensive strategies against elements that
could cause dysbiosis. There is an increasing amount
of research in this area, but the complexity of GI tract
microbial ecology requires further understanding. For
example, recent evidence in a tilapia model suggests
that abrupt interruption of a probiotic administration
can cause gut dysbiosis by increasing host susceptibil-
ity to pathogens and other alterations in the intestinal
epithelium and metabolites.144 It needs to be taken
into consideration whether these results can be
extended to humans when designing probiotic
treatments.
Bacteriocins can control and protect from specific
infections. Microcins have recently proved their ability
to act as narrow-spectrum antimicrobials to limit the
proliferation of Enterobacteriaceae during intestinal
inflammation by giving E. coli Nissle 1917, a probiotic
originally isolated from the human gut, a competitive
advantage.145 This is the first evidence of the ecologi-
cal role that microcins might play in the gut and opens
a door to further therapeutical applications.
An example of the regulatory potential of bacterio-
cins in gut microbial populations is bactofencin A. It
is produced from a L. salivarius isolated from porcine
intestine and, when tested in a distal colon model,
although it did not have a direct inhibitory activity
against Clostridium, Bacteroides, Bifidobacterium and
Fusobacterium, their populations were altered in a
positive way.146 More recently, in an experiment
where water administered to mice was supplemented
with different bacteriocin producer strains, initial 16S
rDNA analysis at phylum level suggested that gut
microbiota populations were not affected. But a
deeper analysis at lower taxonomic levels showed that
potential problematic bacteria, like Clostridium spp.
or Staphylococcus spp., were inhibited.147 The consen-
sus is that we do not see large changes in in vivo
experiments at the level of higher taxonomy level, but
there are certainly beneficial and subtle changes that
are favorable for the host without major disturbances
in the gut, which is a desirable feature. Also, these
studies teach us the importance of the scale of analysis
to understand effects on the gut microbiome.
One of the main challenges for bacteriocin production
in situ is that the producer, in order to be effective, needs
to survive and colonize the human gut and the antimi-
crobial to be active in the gut environment. Thuricin CD
illustrates this assertion. Despite its efficacy against C. dif-
ficile, when delivering B. thuringiensis DPC6431 directly
through the GI tract of mice, results showed that this
approach was not a good delivery option.148 However,
alternative routes were found to be effective, like rectal
administration.148 Also, other possibilities can be
explored, like synbiotics and delivery systems to help pro-
tect the producer strain or the compound from harsh
acidic and enzymatic environments of the GI tract. Tab-
lets of nisin with a pectin / HPMC polymer mixture are
an example of this delivery strategy.149
6. Concluding remarks
The search for new antimicrobials has become one of
the most urgent tasks to address the challenges of
antibiotic resistance. Understanding the environment
where problematic bacteria grow and searching for
the strategies used by their natural enemies to control
them has proven successful. Translating this idea
into practical solutions against acute infections and
systemic syndromes will be supported by the identifi-
cation of different antimicrobials of human micro-
biota origin. Bacteriocins are highly promising, due
to the variety of advantages that they present. Cur-
rent limitations in the identification and isolation of
these compounds can be addressed by incorporating
new techniques like genomic and bioinformatics
tools, genome mining and metagenomics, but there
is the need to translate the genomic information into
the laboratory, and ultimately to achieve efficacy in
vivo. In addition, further understanding of the
microbial ecology of the system under study may
lead to the development of more effective treatments,
both for targeted intervention and to maintain gut
homeostasis.
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